Buccarelli Mariachiara, Castellani Giorgia, Ricci-Vitiani Lucia
Department of Oncology and Molecular Medicine, Istituto Superiore di Sanità, Viale Regina Elena, 299, 00161 Rome, Italy.
Department of Neurosurgery, Fondazione Policlinico Universitario A. Gemelli IRCCS, Università Cattolica del S. Cuore, Largo A. Gemelli, 8, 00168 Rome, Italy.
J Pers Med. 2022 Oct 1;12(10):1625. doi: 10.3390/jpm12101625.
Angiogenesis has long been implicated as a crucial process in GBM growth and progression. GBM can adopt several strategies to build up its abundant and aberrant vasculature. Targeting GBM angiogenesis has gained more and more attention in anti-cancer therapy, and many strategies have been developed to interfere with this hallmark. However, recent findings reveal that the effects of anti-angiogenic treatments are temporally limited and that tumors become refractory to therapy and more aggressive. In this review, we summarize the GBM-associated neovascularization processes and their implication in drug resistance mechanisms underlying the transient efficacy of current anti-angiogenic therapies. Moreover, we describe potential strategies and perspectives to overcome the mechanisms adopted by GBM to develop resistance to anti-angiogenic therapy as new potential therapeutic approaches.
长期以来，血管生成一直被认为是胶质母细胞瘤（GBM）生长和进展的关键过程。GBM可采用多种策略来构建其丰富且异常的脉管系统。在抗癌治疗中，靶向GBM血管生成已受到越来越多的关注，并且已经开发出许多策略来干扰这一特征。然而，最近的研究结果表明，抗血管生成治疗的效果在时间上是有限的，肿瘤会对治疗产生耐药性并变得更具侵袭性。在本综述中，我们总结了与GBM相关的新生血管形成过程及其在当前抗血管生成疗法短暂疗效背后的耐药机制中的作用。此外，我们描述了作为新的潜在治疗方法来克服GBM对抗血管生成治疗产生耐药性所采用机制的潜在策略和前景。
